Trial Profile

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2025 According to a Nkarta Therapeutics Media Release, preliminary clinical data from this study is planned for 2H 2025, and is expected to include clinical response with available follow-up from a group of patients of this study.
07 Nov 2024 According to a Nkarta Therapeutics media release, first patient has been dosed.
13 Aug 2024 According to a Nkarta Therapeutics Media Release, preliminary clinical data from this trial planned for 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com